Compositions and methods for treating cancer with anti-CD33 immunotherapy
AssigneesLentigen Technology, Inc., The United States of America, as represented by the Secretary, Dept. of Health and Human Services
InventorsRimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Claims10
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising, from N-terminus to C-terminus:
- (i) at least one extracellular antigen binding domain comprising a CD33 antigen binding domain encoded by the nucleotide sequence consisting of SEQ ID NO. 1, 3, 5, 7, 9, or 11:
- (ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the T-cell receptor (TCR) alpha chain, the TCR betachain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
- (iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof;
- and
- (iv) an intracellular signaling domain comprising a functional domain selected from the group consisting of a 4-1BB (CD137);
- CD28, and CD3 zeta signaling domain, or a combination thereof.
A method of treating a cancer expressing CD33 in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-tumor effective amount of a population of T cells, wherein the T cells comprise a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises, from N-terminus to C-terminus:
- (i) at least one extracellular antigen binding domain comprising a CD33 antigen binding domain comprising the amino acid sequence selected from the group consisting of SEQ ID NO. 2, 4, 6, 8, 10, and 12:
- (ii) a transmembrane domain comprising a transmembrane domain of a protein selected from the group consisting of the TCR alpha chain, the TCR beta chain, the TCR zeta chain, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, or any combination thereof;
- (iii) at least one costimulatory domain comprising a functional signaling domain selected from the group consisting of OX40, CD70, CD27, CD28, CD5, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), DAP10, DAP12, and 4-1BB (CD137), or any combination thereof;
- and
- (iv) an intracellular signaling domain comprising a functional domain selected from the group consisting of a 4-1BB (CD137);
- CD28, and CD3 zeta signaling domain, or a combination thereof,
- wherein the T cells are T cells of the subject having cancer, wherein the cancer is leukemia.
Dependencies are inferred from the claim text.